Lupin posts Q4FY23 consolidated PAT up at Rs. 235.96 Cr
The company has reported total income of Rs. 4467.35 crores during the quarter ended March 31, 2023
The company has reported total income of Rs. 4467.35 crores during the quarter ended March 31, 2023
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
The Awards recognizes standout digital health & medical technology products and companies
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer
The certification issued by the EDQM verifies the compliance of pharmaceutical substances
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
Krsnaa Diagnostics has commenced its fourth out of eight Diagnostics Center in Ayodhya
Launches Thalassemia Bal Sewa Yojana portal and releases standard treatment guidelines for sickle cell anemia disease
The acquisition of Medisol is part of Lupin's strategy to expand its presence in the EU
Subscribe To Our Newsletter & Stay Updated